Harvard Apparatus Regenerative Technology, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 13, 2026.
Key Highlights
- Cash position: Cash and cash equivalents stood at $1,851 thousand as of September 30, 2026, up from $1,352 thousand at December 31, 2025, according to the filing.
- Shares outstanding: As of November 2, 2026, the company reported 20,093,994 shares of common stock, par value $0.01 per share, outstanding.
- Accounts receivable: The filing reported accounts receivable of $18 thousand at September 30, 2026, compared with $16 thousand at December 31, 2025.
- Inventory: Inventory was reported at zero as of September 30, 2026, down from $16 thousand at December 31, 2025.
- Prepaid research and development: Prepaid R&D increased to $83 thousand at September 30, 2026 from $18 thousand at December 31, 2025.
- Exchange listing: The company disclosed that no securities are registered pursuant to Section 12(b) of the Act, with N/A listed for exchange and trading symbol.
Harvard Apparatus Regenerative Technology Reports September 30, 2026 Balance Sheet Details
Harvard Apparatus Regenerative Technology, Inc., a Delaware-incorporated smaller reporting company headquartered at 84 October Hill Road, Suite 11, Holliston, MA 01746, filed its quarterly report covering the period ended September 30, 2026. According to the filing, the company holds Commission file number 001-35853 and is classified as a non-accelerated filer and smaller reporting company. The filing confirms the company is not an emerging growth company and is not a shell company.
The condensed consolidated balance sheet, presented in thousands, shows cash and cash equivalents of $1,851 thousand at September 30, 2026, compared with $1,352 thousand at December 31, 2025. The filing reports accounts receivable of $18 thousand at the quarter-end date versus $16 thousand at year-end 2025. Inventory was reported at zero as of September 30, 2026, down from $16 thousand at December 31, 2025. Prepaid research and development increased to $83 thousand from $18 thousand over the same period, while prepaid expenses and other current assets declined to $350 thousand from $427 thousand.
The filing includes forward-looking statements, which the company identifies as subject to risks and uncertainties. As disclosed, these statements "are based on the beliefs and assumptions of our management team" and "are not guarantees of performance." The company lists among its forward-looking topics its ability to raise additional capital, continue as a going concern, obtain regulatory approvals, and compete in regenerative medicine and bioengineering. The company states it "undertake[s] no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law."
What Was Disclosed
The filing is a Form 10-Q for the quarter ended September 30, 2026, disclosing balance sheet data including a cash position of $1,851 thousand, zero inventory, and 20,093,994 common shares outstanding as of November 2, 2026. No securities are registered on a national exchange.




Please wait processing your request...